| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
12.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$141.8 - $266.78 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oyler John |
Chief Executive Officer |
• • – |
2024-04-11 |
4 |
AS |
$146.09 |
$1,773,085 |
I/I |
(12,084) |
0 |
|
-3% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2024-04-10 |
4 |
AS |
$148.40 |
$3,977,861 |
I/I |
(26,716) |
12,084 |
|
-6% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2024-04-09 |
4 |
AS |
$152.28 |
$1,724,078 |
I/I |
(11,200) |
38,800 |
|
-8% |
|
| Ball Titus B. |
Principal Accounting OfficerOf |
• – – |
2024-03-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,478 |
|
-20% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2024-03-13 |
4 |
AS |
$176.35 |
$2,189,648 |
D/D |
(12,332) |
0 |
|
-20% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2024-03-12 |
4 |
AS |
$162.74 |
$6,178,369 |
D/D |
(37,668) |
12,332 |
|
-14% |
|
| Glazer Donald W. |
Director |
– • – |
2024-03-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
82,020 |
2,702,123 |
|
- |
|
| Wang Julia Aijun |
Chief Financial Officer |
• – – |
2024-02-29 |
4 |
S |
$167.08 |
$66,331 |
D/D |
(397) |
0 |
|
19% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(172,372) |
0 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-11-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
71,890 |
5,459,438 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2023-11-14 |
4 |
S |
$180.50 |
$198,550,000 |
I/I |
(1,100,000) |
9,691,294 |
|
24% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2023-07-31 |
4 |
S |
$216.26 |
$171,059 |
D/D |
(791) |
0 |
|
15% |
|
| Wang Julia Aijun |
Chief Financial Officer |
• – – |
2023-07-03 |
4 |
S |
$179.55 |
$84,747 |
D/D |
(472) |
0 |
|
-11% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2023-06-26 |
4 |
S |
$181.91 |
$201,567 |
D/D |
(1,108) |
0 |
|
-1% |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2023-06-26 |
4 |
S |
$182.37 |
$272,636 |
D/D |
(1,495) |
0 |
|
-1% |
|
| Wang Julia Aijun |
Chief Financial Officer |
• – – |
2023-06-23 |
4 |
S |
$182.85 |
$153,594 |
D/D |
(840) |
0 |
|
-4% |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2023-06-23 |
4 |
AS |
$180.74 |
$105,381 |
D/D |
(578) |
0 |
|
4% |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2023-06-14 |
4 |
S |
$207.72 |
$56,857,986 |
I/I |
(273,728) |
142,888,241 |
|
19% |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2023-06-13 |
4 |
S |
$128.43 |
$169,448,353 |
I/I |
(924,400) |
143,161,969 |
|
22% |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2023-06-12 |
4 |
S |
$130.83 |
$244,057,178 |
I/I |
(1,250,212) |
144,086,369 |
|
26% |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2023-06-09 |
4 |
S |
$130.35 |
$99,244,890 |
I/I |
(542,652) |
145,336,581 |
|
22% |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2023-06-08 |
4 |
S |
$218.14 |
$253,881,790 |
I/I |
(1,163,825) |
145,879,233 |
|
21% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2023-06-07 |
4 |
S |
$223.23 |
$103,828 |
D/D |
(462) |
0 |
|
22% |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2023-06-07 |
4 |
S |
$223.23 |
$739,599 |
D/D |
(3,291) |
0 |
|
22% |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2023-05-08 |
4 |
S |
$253.72 |
$1,776,037 |
D/D |
(7,000) |
0 |
|
21% |
|
527 Records found
|
|
Page 1 of 22 |
|
|
4.35 (3.14%) 
